(R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”

Adiposity is increased and osteoblast-occupied bone surface is decreased within the external fracture callus during late stage healing in HFD-fed mice. by Matthew L. Brown (431187)

Dysfunction of <i>ERG251</i> activates a Zinc transporter contributing to decreased azole susceptibility. by Xin Zhou (54275)

Radiation induces an increase in splenic regulatory T cells with a decrease in T cell proliferation. by Yu Zhou (89766)

Equilibrium points and their corresponding eigenvalues of Eq (5). by Xinghua Fan (7344632)

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overexpression of PR decreases Myc expression and activity. by Tamar Kavlashvili (849072)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: